Market Overview
Intestinal pseudo-obstruction is a disorder caused by muscle or nerve problem which affects the movement of substances into the intestine. Intestinal pseudo-obstruction mimics the symptoms as those caused in the bowel.
Intestinal pseudo-obstruction can occur at any age but mostly affects older aged. Impairment of nerve, muscles or intestine cells of Cajal causes intestinal pseudo-obstruction disease.
Its symptoms can be abdominal pain, nausea, vomiting, constipation and bloating. Intestinal pseudo-obstruction can be diagnosed by colonoscopy, imaging studies, anorectal manometry, gastric emptying tests, blood test and biopsy.
Intestinal pseudo-obstruction treatment includes nutritional support, Pharmacological therapy and in some cases surgery is preferred.
Prokinetics drugs like erythromycin, metoclopramide, domperidone and lubiprostone are the most prescribed drug in the Intestinal pseudo-obstruction treatment market. Another drug cisapride has been reported for a positive result but is currently available only in a few parts of the world.
Over the last few years, many advances have been made to treat diagnose and treat intestinal pseudo-obstruction disorder.
Intestinal Pseudo-obstruction Treatment Market: Drivers and Restraints-
Increasing prevalence of the gastrointestinal disease is expected to drive the Intestinal pseudo-obstruction treatment market.Rising cases of Parkinson’s disease, collagen vascular and others is expected to boost the intestinal pseudo-obstruction treatment market.
There are many infections which leads to Intestinal pseudo-obstruction disease, therefore increasing infectious disease is expected to drive the growth of the Intestinal pseudo-obstruction treatment market.
Cost-effective diagnosis and treatment also act as a driver in Intestinal pseudo-obstruction treatment market. As it mimics bowel, lack of awareness about the disorder can hamper the growth of the market Intestinal pseudo-obstruction treatment market.
Intestinal Pseudo-obstruction Treatment Market: Overview
Based on drug class, antibiotics are expected to be the most preferred drug in the Intestinal pseudo-obstruction treatment market. Based on the route of administration, the oral route is the most frequently used route of drug administration in the Intestinal pseudo-obstruction treatment market.
Based on the distribution channel, retail pharmacies are expected to be the most profitable segment in the global Intestinal pseudo-obstruction treatment market.Over the last several decades, diagnosis and treatment of Intestinal pseudo-obstruction disorder have improved.
Many researchers are trying to study the role of the intestinal pacemaker, which follow the same principle of cardiac pacemakers. Early studies have improvements in vomiting and nausea condition in intestinal pseudo-obstruction disorder. As it requires many specialists, the disease has to be confirmed by several numbers of test.
Therefore, researches are conducted for developing new therapies for early diagnosis and treatment of intestinal pseudo-obstruction disorder. Scientists are studying the behavioural approach for pain management.
It is reported that nutrition support is the mainstay in the management of intestinal pseudo-obstruction treatment, so management of nutrition has become the main focus of the market.
Intestinal Pseudo-obstruction TreatmentMarket: Region-wise Outlook
North America and Europe are expected to dominate the intestinal pseudo-obstruction treatment market, owing to the prominent technological advancements, innovations. High prevalence rates of chronic digestive disorder require patient diagnosing and treatment is expected to increase the growth of the Intestinal pseudo-obstruction market in these regions.
Increase in healthcare expenditure and also increasing population in developing region like Asia-Pacific is expected to further push intestinal pseudo-obstruction market growth for over the forecast period.
Intestinal Pseudo-obstruction Treatment Market: Key Market Participants
Some of the market participants in the global intestinal pseudo-obstruction treatment market identified across the value chain include:
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Abbott Laboratories
- Pfizer Inc.
- Johnson & Johnson
- Callisto Pharmaceuticals Inc.
- Biogen Inc.
- Novartis A.G
- Canila Healthcare Ltd
The report covers exhaust analysis on:
- Intestinal Pseudo-obstruction Treatment Market Segments
- Intestinal Pseudo-obstruction Treatment Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (India, ASEAN, Australia & New Zealand)
- China
- Japan
- Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
Impact of Covid-19 on Intestinal pseudo-obstruction treatment
Pandemic coronavirus has caused a disturbance in almost all the industries. COVID-19 has various implications for the digestive system. Studies have found that gastrointestinal symptoms occur in COVID-19 patients.
Also in some cases, digestive problems appear prior to respiratory symptoms. People with the chronic digestive disorder are more vulnerable to coronavirus as a result people are getting more concern about maintaining their digestive health.
It would provide more opportunities for every segment in the intestinal pseudo-obstruction treatment market. So COVID-19 is expected to have a positive impact on intestinal pseudo-obstruction treatment market.
Report Highlights:
- Detailed overview of parent market
- Changing Intestinal pseudo-obstruction market dynamics in the industry
- Intestinal pseudo-obstruction treatment-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Intestinal pseudo-obstruction treatment recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Intestinal Pseudo-obstruction TreatmentMarket: Segmentation
By drug class
- Antibiotics
- Antidepressants
- Antidiarrheals
By administration
- Oral
- Injectable
By distribution channels
- Hospital Pharmacies
- Retail Pharmacies
- Drug store
- Online sales
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports